Although they are not even on the market yet in the U.S., biosimilars are already taking center stage when it comes to politics.
Proposed legislation in Colorado would allow pharmacists there to substitute generic biotech drugs for brand-name biologicals if the patient's doctor has access to information about the change.
A similar bill was proposed in 2013, but, according to the Denver Business Journal, "died amid lobbying for and against the measure from big drug companies."
The big difference with the legislation then and now is that drug makers are backing the doctor notification portion of the wording. Previously, some companies argued that notifying the doctor was an unneeded step, and would prevent pharmacists from prescribint a biosimilar.
